Literature DB >> 12940381

Measles, mumps, rubella (MMR) vaccine.

A P Dubey1, S Banerjee.   

Abstract

MMR is a live attenuated vaccine. Indian children show almost 90% seroconversion against measles and rubella and 90% against mumps. Several adverse effects have been reported. Epidemiological studies do not support a causative link between MMR and autism, IBD or GBS. There is an association between the Urabe strain of mumps vaccine and viral meningitis. Vaccine associated thrombocytopenia has been reported. Severe hypersensitivity reactions occur, mainly due to the gelatin component. Outbreaks of measles occur in areas of high measles vaccine coverage, when susceptible individuals accumulate. A second dose is given mainly to vaccinate those who missed the first dose or had primary vaccine failure, rather than to boost waning antibody levels. The possibility or eradication of mumps with a second dose of mumps vaccine is being considered.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12940381     DOI: 10.1007/bf02723162

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  24 in total

Review 1.  Crohn's disease: the case for measles virus.

Authors:  A J Wakefield; S M Montgomery; R E Pounder
Journal:  Ital J Gastroenterol Hepatol       Date:  1999-04

2.  General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP).

Authors:  William L Atkinson; Larry K Pickering; Benjamin Schwartz; Bruce G Weniger; John K Iskander; John C Watson
Journal:  MMWR Recomm Rep       Date:  2002-02-08

3.  MMR and autism: an overview of the debate to date.

Authors:  Anastasia T Phelan
Journal:  Br J Nurs       Date:  2002 May 9-22

4.  Update: International Task Force for Disease Eradication, 1990 and 1991.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1992-01-24       Impact factor: 17.586

5.  Changes of the immunological patterns against measles, mumps and rubella. A vaccination programme studied 3 to 7 years after the introduction of a two-dose schedule.

Authors:  B Christenson; M Böttiger
Journal:  Vaccine       Date:  1991-05       Impact factor: 3.641

6.  Neurologic disorders after measles-mumps-rubella vaccination.

Authors:  Annamari Mäkelä; J Pekka Nuorti; Heikki Peltola
Journal:  Pediatrics       Date:  2002-11       Impact factor: 7.124

7.  Paramyxovirus infections in childhood and subsequent inflammatory bowel disease.

Authors:  S M Montgomery; D L Morris; R E Pounder; A J Wakefield
Journal:  Gastroenterology       Date:  1999-04       Impact factor: 22.682

8.  Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow-up.

Authors:  A Patja; I Davidkin; T Kurki; M J Kallio; M Valle; H Peltola
Journal:  Pediatr Infect Dis J       Date:  2000-12       Impact factor: 2.129

9.  Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States.

Authors:  Vitali Pool; M Miles Braun; John M Kelso; Gina Mootrey; Robert T Chen; John W Yunginger; Robert M Jacobson; Paul M Gargiullo
Journal:  Pediatrics       Date:  2002-12       Impact factor: 7.124

Review 10.  Neurological complications of immunization.

Authors:  G M Fenichel
Journal:  Ann Neurol       Date:  1982-08       Impact factor: 10.422

View more
  2 in total

1.  Low rate of seropositivity (IgG) to mumps component in MMR vaccinees in Chennai, south India.

Authors:  Jeevan Malaiyan; Thatchayini Duraipandian; Aparna Warrier; Thangam Menon
Journal:  Indian J Med Res       Date:  2014-06       Impact factor: 2.375

2.  Uptake of newer vaccines in Chandigarh.

Authors:  Sonia Puri; Vikas Bhatia; Amarjit Singh; H M Swami; Amrit Kaur
Journal:  Indian J Pediatr       Date:  2007-01       Impact factor: 5.319

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.